US 11,945,789 B2
Inhibitors of the IRE-1/XBP-1 pathway and methods of using thereof
Juan R. Del Valle, Tampa, FL (US); and Chih-Chi Andrew Hu, Tampa, FL (US)
Assigned to H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC., Tampa, FL (US)
Filed by H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC., Tampa, FL (US)
Filed on Mar. 18, 2019, as Appl. No. 16/356,318.
Application 16/356,318 is a continuation of application No. 14/786,561, granted, now 10,323,013, previously published as PCT/US2014/035164, filed on Apr. 23, 2014.
Claims priority of provisional application 61/975,563, filed on Apr. 4, 2014.
Claims priority of provisional application 61/875,080, filed on Sep. 8, 2013.
Claims priority of provisional application 61/814,883, filed on Apr. 23, 2013.
Prior Publication US 2020/0024247 A1, Jan. 23, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/00 (2006.01); A01K 67/0276 (2024.01); A61K 31/37 (2006.01); A61K 31/395 (2006.01); A61K 31/436 (2006.01); A61K 31/519 (2006.01); A61K 31/52 (2006.01); A61K 31/55 (2006.01); A61K 33/243 (2019.01); A61K 45/06 (2006.01); C07D 311/16 (2006.01); C07D 311/18 (2006.01); C07D 491/052 (2006.01)
CPC C07D 311/16 (2013.01) [A01K 67/0276 (2013.01); A61K 31/37 (2013.01); A61K 31/395 (2013.01); A61K 31/436 (2013.01); A61K 31/519 (2013.01); A61K 31/52 (2013.01); A61K 31/55 (2013.01); A61K 33/243 (2019.01); A61K 45/06 (2013.01); C07D 311/18 (2013.01); C07D 491/052 (2013.01); A01K 2217/075 (2013.01); A01K 2217/077 (2013.01); A01K 2227/105 (2013.01); A01K 2267/0331 (2013.01)] 49 Claims
OG exemplary drawing
 
1. A compound having Formula IV:

OG Complex Work Unit Chemistry
wherein
A is a chalcogen containing moiety; and
R5 is chosen from hydrogen, benzyl, substituted benzyl, benzoate, alkyl, heteroalkyl, alkenyl, heteroalkenyl, alkynyl, haloalkyl, cycloalkyl, heterocycloalkyl, alkylaryl, aryl, alkylheteroaryl, or heteroaryl, any of which is optionally substituted with acetyl, alkyl, amino, amido, —NR6R7, —C(O)NR6R7, alkoxy, alkylhydroxy, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, carbonyl, halo, hydroxy, thiol, cyano, or nitro; or
a pharmaceutically acceptable salt thereof.